ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT

• Status: Enrolling by invitation
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Weight control is an essential part of treatment for type 2 diabetes (T2D) patients. Weight loss is associated with decreased haemoglobin A1c (A1c) levels. In particular, visceral fat is accompanied by more alterations in glucose and lipid metabolism. Quantification of visceral fat with bioimpedance (BIA) is closely related to measurement with computed axial tomography. Different available oral antidiabetics cause weight loss and total body fat (biguanides, DPP-4 inhibitors and SGLT-2 inhibitors), but it has only been shown that SLGT2 inhibitors decrease visceral fat. Therefore, the aim of this study is to determine whether there is a difference in the amount of visceral fat measured with BIA in T2D patients between three oral antidiabetic regimens after twelve weeks of treatment, to compare the effect on visceral fat between metformin, DPP4 inhibitors and SGLT2 inhibitors.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Metabolic Research Unit
• Treatments: Biguanides; Dipeptidyl-Peptidase IV Inhibitors; Sodium-Glucose Transporter 2 Inhibitors

Criteria

Inclusion Criteria:

• Adult patients +18 years

• Patients with visceral fat quantification by BIA at baseline and week twelve

• Patients with body mass index >25

• Patients can swallow tablets

Exclusion Criteria:

• Patients treated with other oral antidiabetic agents or insulin

• Glomerular filtration rate less than 30 mL/min

• Transaminemia greater than 2 times the upper reference value

• Pregnancy

• Malnutrition